Evidence map›Paper›PMID 38592525›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes.

Tiffany Li, Terry Trinh, Annmarie Bosco, Matthew C Kiernan, David Goldstein, Susanna B Park

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Nerve cross-sectional area in vincristine-induced polyneuropathy: A nerve ultrasound pilot study.Journal of neuroimaging : official journal of the American Society of Neuroimaging
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tiffany LiBrain and Mind Centre, The University of Sydney, Sydney, Australia.
Terry TrinhPrince of Wales Clinical School, University of New South Wales, Kensington, Australia.
Annmarie BoscoPrince of Wales Clinical School, University of New South Wales, Kensington, Australia.
Matthew C KiernanBrain and Mind Centre, The University of Sydney, Sydney, Australia.
David GoldsteinPrince of Wales Clinical School, University of New South Wales, Kensington, Australia.
Susanna B ParkBrain and Mind Centre, The University of Sydney, Sydney, Australia. Susanna.park@sydney.edu.au.
UNSW Sydney · AUUniversity of Sydney · AURoyal Prince Alfred Hospital · AU

Funding

Cancer Institute NSW 2021/CBG0002Cancer Institute NSW Program Grant 14/TPG/1-05National Health and Medical Research Council 1132524National Health and Medical Research Council 1148595National Health and Medical Research Council, Australia 1156093
6 · The paper itself

Abstract

backgroundDecades following the introduction of vincristine as treatment for haematological malignancies, vincristine-induced peripheral neuropathy (VIPN) remains a pervasive, untreatable side-effect. However there remains a gap in understanding the characteristics of VIPN in adults. This study presents a comprehensive phenotyping of VIPN.

methodsAdult patients (n = 57; age = 59.8 ± 14.6) were assessed cross-sectionally following completion of vincristine (months post treatment = 16.3 ± 15.6, cumulative dose = 7.6 ± 4.4), with a subset of 20 patients assessed prospectively during treatment. Patient reported measures (EORTC-QLQ-CIPN20, R-ODS) were used to profile symptoms and disability. Neurological assessment was undertaken using the Total Neuropathy Score and nerve conduction studies. Sensory threshold and fine motor tasks were also undertaken. Comparisons of data between timepoints were calculated using paired-sample t tests or Wilcoxon matched-pairs signed-rank test. Comparisons between outcome measures were calculated with independent sample t tests or Mann-Whitney U tests for non-parametric data.

resultsThe majority of patients developed VIPN by mid-treatment (77.8%, 7.0 ± 3.3 weeks post baseline) with the prevalence remaining stable by end-of-treatment (75%, 8.1 ± 1.7 weeks post mid-treatment). By 3 months post-completion, 50% of patients still reported VIPN although there were significant improvements on neurological grading and functional assessment (P < 0.05). VIPN presented with sensorimotor involvement in upper and lower limbs and was associated with decreased sensory and motor nerve amplitudes, reduced fine-motor function and increased disability.

conclusionVIPN in adults presents as a sensorimotor, upper- and lower-limb neuropathy that significantly impacts disability and function. Neuropathy recovery occurs in a proportion of patients; however, VIPN symptoms may persist and continue to affect long-term quality of life.

Indexed as

Hematologic NeoplasmsPeripheral Nervous System DiseasesAdultAgedHumansLower ExtremityMiddle AgedQuality of LifeVincristineVincristineNatural historyNerve conductionPatient reported outcomesPhenotypeVincristine-induced peripheral neuropathy

Identifiers

PMID38592525
PMCPMC11003903
OpenAlexW4394620662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.